EPHA1 and colorectal carcinoma: For EPHB2, small-molecule inhibitors like STA-013,[49] dasatinib[50] and GLPG1790 (pan-Eph antagonist reducing cancer stem cells)[51] are available, demonstrating antitumor effects in CRC and potential to modulate autoimmune inflammation.